Teva Pharmaceutical Industries (TEVA) Other Non-Current Liabilities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Other Non-Current Liabilities for 18 consecutive years, with $3.7 billion the latest figure, recorded in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 7.53% year-over-year to $3.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 billion (down 7.53% YoY) and the FY2025 annual result came in at $3.8 billion, down 5.46% from the prior year.
• Other Non-Current Liabilities eased to $3.7 billion in Q1 2026 per TEVA's latest filing, from $3.8 billion in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for TEVA reached as high as $4.4 billion in Q2 2024 and fell as low as $3.3 billion in Q1 2022.
• A 5-year average of $3.9 billion and a median of $4.0 billion in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 75.17% — and 2025, when it fell 15.65%.
• Year by year, Other Non-Current Liabilities stood at $3.9 billion in 2022, then advanced by 1.88% to $4.0 billion in 2023, then rose by 0.22% to $4.0 billion in 2024, then retreated by 5.46% to $3.8 billion in 2025, then declined by 2.6% to $3.7 billion in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3.7 billion, $3.8 billion, and $3.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.